161 related articles for article (PubMed ID: 35709921)
1. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
Jia R; Zhang X; Xu Y; Zheng Z; Jiang L; Zhang X; Sun C; Wu X; Li S; Raj A; Sun D
Eur J Pharmacol; 2022 Aug; 928():175053. PubMed ID: 35709921
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.
Lee WC; Liao TW; Chen TY; Fang HY; Fang YN; Chen HC; Lin YS; Chang SH; Chen MC
Cardiovasc Drugs Ther; 2024 Jun; 38(3):505-515. PubMed ID: 36609948
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.
Zhou W; Yang X; Jin J; Cheng M; Li Y; Bai Y; Xu J
Int Urol Nephrol; 2024 Jan; 56(1):181-190. PubMed ID: 37195574
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Mou Y; Qin L; Wang L; Guo Y; Zhang X; Yu J
Altern Ther Health Med; 2024 Apr; 30(4):190-197. PubMed ID: 37917889
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Solomon SD; Braunwald E;
J Am Coll Cardiol; 2023 Jul; 82(1):1-12. PubMed ID: 37212758
[TBL] [Abstract][Full Text] [Related]
6. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
Morrow DA; Velazquez EJ; Desai AS; DeVore AD; Lepage S; Park JG; Sharma K; Solomon SD; Starling RC; Ward JH; Williamson KM; Zieroth S; Hernandez AF; Mentz RJ; Braunwald E
J Am Coll Cardiol; 2024 Mar; 83(12):1123-1132. PubMed ID: 38508844
[TBL] [Abstract][Full Text] [Related]
7. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.
Chatur S; Neuen BL; Claggett BL; Beldhuis IE; Mc Causland FR; Desai AS; Rouleau JL; Zile MR; Lefkowitz MP; Packer M; McMurray JJV; Solomon SD; Vaduganathan M
J Am Coll Cardiol; 2024 Jun; 83(22):2148-2159. PubMed ID: 38588927
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
Vaduganathan M; Mentz RJ; Claggett BL; Miao ZM; Kulac IJ; Ward JH; Hernandez AF; Morrow DA; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Lefkowitz M; McMurray JJV; Braunwald E; Solomon SD
Eur Heart J; 2023 Aug; 44(31):2982-2993. PubMed ID: 37210743
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
Foà A; Vaduganathan M; Claggett BL; Pabon MA; Lu H; Pfeffer MA; Packer M; Vardeny O; Rouleau JL; Lefkowitz M; Mentz RJ; Jhund PS; Desai AS; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2024 May; 83(18):1731-1739. PubMed ID: 38537919
[TBL] [Abstract][Full Text] [Related]
10. The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis.
Yang X; Jin J; Cheng M; Xu J; Bai Y
Ren Fail; 2024 Dec; 46(1):2349135. PubMed ID: 38869007
[TBL] [Abstract][Full Text] [Related]
11. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.
Senni M; McMurray JJ; Wachter R; McIntyre HF; Reyes A; Majercak I; Andreka P; Shehova-Yankova N; Anand I; Yilmaz MB; Gogia H; Martinez-Selles M; Fischer S; Zilahi Z; Cosmi F; Gelev V; Galve E; Gómez-Doblas JJ; Nociar J; Radomska M; Sokolova B; Volterrani M; Sarkar A; Reimund B; Chen F; Charney A
Eur J Heart Fail; 2016 Sep; 18(9):1193-202. PubMed ID: 27170530
[TBL] [Abstract][Full Text] [Related]
12. Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial.
Ostrominski JW; Claggett BL; Packer M; Pfeffer MA; Lam CSP; Zile MR; Desai AS; Jhund PS; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
J Card Fail; 2023 Nov; 29(11):1494-1503. PubMed ID: 37220823
[TBL] [Abstract][Full Text] [Related]
13. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
UK HARP-III Collaborative Group
Nephrol Dial Transplant; 2017 Dec; 32(12):2043-2051. PubMed ID: 27646835
[TBL] [Abstract][Full Text] [Related]
14. Effect of Sacubitril/Valsartan on Patients Having Heart Failure With Preserved Left Ventricular Ejection Fraction Undergoing Hemodialysis: A Long-term Observational Study.
Mima A; Gotoda H; Lee S; Lee R; Murakami A; Akai R; Kidooka S; Matsumoto K; Saito Y; Hishida S; Nakamoto T; Kido S; Hamada T
In Vivo; 2024; 38(3):1266-1270. PubMed ID: 38688596
[TBL] [Abstract][Full Text] [Related]
15. Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study.
Straburzynska-Migaj E; Senni M; Wachter R; Fonseca C; Witte KK; Mueller C; Lonn E; Butylin D; Noe A; Schwende H; Lawrence D; Suryawanshi B; Pascual-Figal D;
J Card Fail; 2024 Mar; 30(3):425-435. PubMed ID: 37678704
[TBL] [Abstract][Full Text] [Related]
16. Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF.
Liu H; Su Y; Shen J; Jiao Y; Li Y; Liu B; Hou X; Jin Q; Chen Y; Sun Z; Xi Q; Feng B; Fu Z
ESC Heart Fail; 2024 Apr; 11(2):937-949. PubMed ID: 38224955
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: A PRISMA-compliant article.
Lin J; Zhou J; Xie G; Liu J
Medicine (Baltimore); 2021 Dec; 100(52):e28231. PubMed ID: 34967357
[TBL] [Abstract][Full Text] [Related]
18. Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis.
Charuel E; Menini T; Bedhomme S; Pereira B; Piñol-Domenech N; Bouchant S; Boussageon R; Bœuf-Gibot S; Vaillant-Roussel H
Pharmacol Res Perspect; 2021 Oct; 9(5):e00844. PubMed ID: 34617669
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril/valsartan can improve the cardiac function in heart failure patients with a history of cancer: An observational study.
Chen Z; Zhang C; Zhu Y; Gao D; Mao M; Zuo Z
Medicine (Baltimore); 2024 Mar; 103(12):e37613. PubMed ID: 38517992
[TBL] [Abstract][Full Text] [Related]
20. Reverse Remodeling Effects of Sacubitril-Valsartan: Structural and Functional Optimization in Stage C Heart Failure.
Kalanatari S; Oren D; Medvedofsky D; Narang A; Imamura T; Tayazime S; Kim GH; Raikhelkar J; Sayer G; Lang RM; Uriel N
Am J Cardiol; 2024 Jan; 210():249-255. PubMed ID: 37884115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
